JP2022535523A5 - - Google Patents

Info

Publication number
JP2022535523A5
JP2022535523A5 JP2021571517A JP2021571517A JP2022535523A5 JP 2022535523 A5 JP2022535523 A5 JP 2022535523A5 JP 2021571517 A JP2021571517 A JP 2021571517A JP 2021571517 A JP2021571517 A JP 2021571517A JP 2022535523 A5 JP2022535523 A5 JP 2022535523A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021571517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535523A (ja
JP7634231B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035323 external-priority patent/WO2020243572A2/en
Publication of JP2022535523A publication Critical patent/JP2022535523A/ja
Publication of JP2022535523A5 publication Critical patent/JP2022535523A5/ja
Priority to JP2025014697A priority Critical patent/JP2025090568A/ja
Application granted granted Critical
Publication of JP7634231B2 publication Critical patent/JP7634231B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571517A 2019-05-31 2020-05-29 Ｐａｎ－ノイラミニダーゼ阻害抗体 Active JP7634231B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025014697A JP2025090568A (ja) 2019-05-31 2025-01-31 Ｐａｎ－ノイラミニダーゼ阻害抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855358P 2019-05-31 2019-05-31
US62/855,358 2019-05-31
PCT/US2020/035323 WO2020243572A2 (en) 2019-05-31 2020-05-29 Pan-neuraminidase inhibiting antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025014697A Division JP2025090568A (ja) 2019-05-31 2025-01-31 Ｐａｎ－ノイラミニダーゼ阻害抗体

Publications (3)

Publication Number Publication Date
JP2022535523A JP2022535523A (ja) 2022-08-09
JP2022535523A5 true JP2022535523A5 (cg-RX-API-DMAC7.html) 2023-06-05
JP7634231B2 JP7634231B2 (ja) 2025-02-21

Family

ID=73552980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571517A Active JP7634231B2 (ja) 2019-05-31 2020-05-29 Ｐａｎ－ノイラミニダーゼ阻害抗体
JP2025014697A Pending JP2025090568A (ja) 2019-05-31 2025-01-31 Ｐａｎ－ノイラミニダーゼ阻害抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025014697A Pending JP2025090568A (ja) 2019-05-31 2025-01-31 Ｐａｎ－ノイラミニダーゼ阻害抗体

Country Status (4)

Country Link
US (1) US12509503B2 (cg-RX-API-DMAC7.html)
EP (1) EP3980441A4 (cg-RX-API-DMAC7.html)
JP (2) JP7634231B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020243572A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7634231B2 (ja) * 2019-05-31 2025-02-21 ワシントン ユニバーシティ Ｐａｎ－ノイラミニダーゼ阻害抗体
WO2023201306A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections
CN119119281B (zh) * 2024-09-02 2025-12-05 中山大学·深圳 抗神经氨酸酶的单克隆抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007295073A1 (en) 2006-09-15 2008-03-20 Fraunhofer Usa, Inc. Influenza antibodies, compositions, and related methods
US8734803B2 (en) * 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
EP2788026A4 (en) * 2011-12-05 2015-08-05 Univ Duke V1V2 IMMUNOGENIC
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
WO2016124682A1 (en) * 2015-02-05 2016-08-11 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
JP7634231B2 (ja) * 2019-05-31 2025-02-21 ワシントン ユニバーシティ Ｐａｎ－ノイラミニダーゼ阻害抗体

Similar Documents

Publication Publication Date Title
JP2018535650A5 (cg-RX-API-DMAC7.html)
FI4045533T3 (fi) Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
JP2011528902A5 (cg-RX-API-DMAC7.html)
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
JP2023515271A5 (cg-RX-API-DMAC7.html)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
JP2023071956A5 (cg-RX-API-DMAC7.html)
JP2012504955A5 (cg-RX-API-DMAC7.html)
JP2010516229A5 (cg-RX-API-DMAC7.html)
JP2018108086A5 (cg-RX-API-DMAC7.html)
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
HRP20201345T1 (hr) Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba
JP2016503413A5 (cg-RX-API-DMAC7.html)
RU2014146503A (ru) Белки, связывающие антиген - лиганд cd30 человека
JP2020500538A5 (cg-RX-API-DMAC7.html)
JP2019504032A5 (cg-RX-API-DMAC7.html)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP2025032102A5 (cg-RX-API-DMAC7.html)
JP2021501579A5 (cg-RX-API-DMAC7.html)
JP2015522252A5 (cg-RX-API-DMAC7.html)
JP2019533425A5 (cg-RX-API-DMAC7.html)
JP2011528901A5 (cg-RX-API-DMAC7.html)
JP2022525377A5 (cg-RX-API-DMAC7.html)
JP2022535523A5 (cg-RX-API-DMAC7.html)